Guangxi LiuYao Group (603368): Tripartite cooperation to promote the implementation of the "AI + Medical" full-scenario application plan, with potential new applications both inside and outside the hospital.

Event: On March 11, Guangxi LiuYao Group, Huawei, and Shanghai Runda Medical Technology held a seminar on the "AI+Healthcare" full scenario application solutions at Guangxi LiuYao Group's Nanning campus. The three parties discussed promoting AI medical large models throughout the entire medical diagnosis and treatment process in the Hospital, both inside and outside.

Cinda SecuritiesMar 13 18:07

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 3 10:09

Express News | Guangxi LiuYao Group: The company has reached a Global Strategy cooperation with Huawei Cloud and Shanghai Runda Medical Technology.

BreakingsFeb 20 16:03

Guangxi LiuYao Group (603368.SH): Some fundraising investment projects have been completed and the surplus fundraising will be permanently used to supplement working capital.

On December 13, Gelonghui announced that Guangxi LiuYao Group (603368.SH) reported the completion and readiness for the "Nanning Traditional Chinese Medicine Decoction Piece Capacity Expansion Project" and the "Chain Pharmacy Expansion Project," which are part of the public issuance of convertible corporate bonds fundraising investment projects (hereinafter referred to as "fundraising projects"). The "Supplementary Working Capital" has been fully utilized. The company will conclude the aforementioned fundraising projects. To meet the demand for working capital for daily production and operation activities, the company plans to use the remaining fundraising funds totaling 57.2102 million yuan (the actual amount will be based on the balance of the fundraising special account on the day of the fund transfer).

Gelonghui FinanceDec 13, 2024 18:49

Not recognized by the capital markets? Guangxi Liuyao Group: The company's stock price does not match its value | Direct coverage of the earnings conference.

1. At the earnings conference, the chairman of guangxi liuyao group, Zhu Chaoyang, stated that the company's market cap, stock price, and company value are not aligned; 2. The company secretary Xu Yang stated that the company will improve the issue of high accounts receivable through measures such as strengthening the assessment of collection indicators for business personnel; 3. Xu Yang introduced the progress of the company's AI application business in response to investors' concerns.

cls.cnDec 9, 2024 20:31

Guangxi Liuyao Group (603368): The three major business segments are gradually improving, accelerating expansion outside the province.

Event: In the third quarter of 2024, guangxi liuyao group achieved revenue of 5.351 billion yuan, a year-on-year increase of 1.49%; achieved net income attributable to the parent of 0.252 billion yuan, a year-on-year increase of 8.68%; in the first three quarters of 2024, achieved revenue

caitong securitiesOct 30, 2024 19:32